Concurrently, based on the evidence linking fatty acid and glutamine metabolism to tumor progression, therapeutic strategies targeting SLC1A5 or CD36 could be integrated with existing chemotherapy or immunotherapy to potentially enhance therapeutic efficacy [46–48]. Here, CD36 is linked to neoplasm.